Browsing Tag
Be Biopharma
3 posts
Be Biopharma reports positive preclinical data for BE-102 in hypophosphatasia
Be Biopharma shares preclinical results for BE-102, a B cell medicine in development for treating hypophosphatasia. Read about its novel approach.
Be Biopharma unveils promising preclinical data for BE-102 B cell therapy targeting hypophosphatasia
In a notable advancement for genetic bone disorder therapies, Be Biopharma Inc. has presented new preclinical data for…
Be Biopharma unveils promising preclinical results for hypophosphatasia treatment using engineered B cell medicines
Be Biopharma, Inc. has presented groundbreaking preclinical findings that underscore the potential of Engineered B Cell Medicines (BCMs)…